Mon Health Medical Center Introduces Aquablation Therapy
Posted Date: 7/22/2022
Mon Health Medical Center announced today that it is the first in North Central West Virginia to offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. One in two men ages 51 to 60 have BPH, and the incidence increases every decade of life. If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones, and incontinence. The problem with BPH surgical treatments today is that they often force men to trade off between symptom relief and side effects, limiting patients to choose between either a high degree of symptom relief with high rates of irreversible complications (such as incontinence, erectile dysfunction, or ejaculatory dysfunction) or low degree of symptom relief with low rates of irreversible complications.
Aquablation therapy is a different type of treatment for BPH with proven results. It’s an advanced, minimally invasive treatment that uses the power of water delivered with robotic precision to provide best-in-class and long-lasting symptom relief with low rates of irreversible complications, applicable to most prostate shapes and sizes.
“At Mon Health Urology, we focus on offering our patients treatments that will improve their quality of life,” said
Dr. Jaschar Shakuri-Rad, Robotic Surgeon and Urologist at Mon Health System. “Aquablation is another tool in our toolbox that will allow us to keep that promise.”
Aquablation therapy is performed by the AquaBeam Robotic System, the first FDA-cleared, surgical robot utilizing automated tissue resection or the treatment of LUTS due to BPH. It combines real-time, multi-dimensional imaging, automated robotic technology, and heat-free waterjet ablation technology for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predicable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience.
A study within the Journal of Sexual Medicine, which surveyed 300 men living with BPH, revealed 92% of respondents expressed an interest in learning more about Aquablation therapy. This data demonstrates the need within the patient population to find relief without having to choose between symptoms or side effects.
“We are excited to offer this advanced treatment to our patients. Our surgeons and teams are known widely for their excellence; offering Aquablation therapy will add to the reasons why patients choose Mon Health for their medical care,” said David Goldberg, President and CEO of Mon Health System.
For more information on Aquablation therapy, visit
aquablation.com.
Popularity:
This record has been viewed 1772 times.